Clinical Trials Logo

Clinical Trial Summary

In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.


Clinical Trial Description

The improved prognostic scoring system has been in use for more than 20 years in GTN patients. However, there are also more and more clinical evidences showing that the International Federation of Obstetrics and Gynecology(FIGO)/world health organization (WHO) system is not so perfect. The main problem is that a considerable number of patients are resistant to initial chemotherapy, 25-35% occur in low risk (≤ 6 points), and 70-80% occur in patients with a score of 5-6 points. According to reference, the drug resistance factors include high HCG level before chemotherapy, metastatic foci, histological diagnosis of choriocarcinoma, etc. However, according to the score before 2000, there is a moderate risk score group with 4-6 points, i.e. most of the single drug resistance to the initial regimen occurs in the previous moderate risk score group.Therefore, most scholars believe that there are grey areas with a score of 5-6. According to the analysis of 5-6 scores in the scoring system, the prognosis of single-drug chemotherapy is poor, and the initial remission rate is only about 30-40%. Therefore, many authors call for the current staging scoring system to be revised to a more accurate model so that some patients who may be drug resistant can adopt more effective plans at the beginning of treatment.

In this study, the investigators plan to conduct a prospective, multicenter randomized controlled study to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen. The experiment arm of the trial is multi-course combination of MTX and ACTD. The primary endpoint is complete remission rate of primary treatment or failure of primary treatment. Drug toxicity is surveillanced. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03885388
Study type Interventional
Source Women's Hospital School Of Medicine Zhejiang University
Contact Weiguo Lu, MD.
Phone 86-13588819218
Email lbwg@zju.edu.cn
Status Recruiting
Phase Phase 2/Phase 3
Start date March 8, 2019
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Recruiting NCT02306837 - Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies Phase 2
Completed NCT02771470 - Intestinal Microflora in Lung Cancer After Chemotherapy Phase 1
Completed NCT02454673 - Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer N/A
Completed NCT02454647 - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients N/A
Completed NCT01432223 - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase 2
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting NCT02555592 - Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level N/A
Suspended NCT02121405 - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Phase 3
Recruiting NCT02226380 - FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer Phase 2
Completed NCT00911352 - Cryotherapy Intervention for Docetaxel-induced Nail Toxicities Phase 2/Phase 3
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Active, not recruiting NCT01490060 - Fosaprepitant in Patients Receiving Ifosfamide-based Regimen N/A
Completed NCT02395341 - The Longitudinal Ovarian Reserve Study N/A
Recruiting NCT05268991 - Aging and Frailty Study
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Enrolling by invitation NCT02074241 - Molecular Markers of Chemosensitivity for Bladder Cancer N/A
Completed NCT01143844 - Assessing Fertility Potential in Female Cancer Survivors
Recruiting NCT02169388 - Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy Phase 1
Completed NCT03402295 - Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation Phase 3